Determination of Beta-Blockers in Urine Using Supercritical Fluid Chromatography and Mass Spectrometry

Importance of the Topic

Urine analysis for beta-blockers is critical in sports doping control and clinical testing. Rapid, sensitive detection of these polar drugs helps enforce anti-doping rules and ensures patient safety in therapeutic monitoring.

Objectives and Overview

This study aimed to develop a fast, robust SFC-MS method for quantifying 13 beta-blockers in urine. Key goals included:

• Evaluating chromatographic separation performance under supercritical fluid conditions
• Determining limits of detection, limits of quantification, and calibration linearity
• Assessing precision, accuracy, and repeatability for real-life urine samples

Methodology

Polar beta-blocker standards were prepared at 1 mg/mL in acetonitrile and diluted for calibration from 1 to 1000 ng/mL. Urine samples were spiked with penbutolol (250 ng/mL), diluted with methanol, vortexed, centrifuged, and filtered prior to injection. The SFC method employed a methanol gradient (2–50% modifier) at 3 mL/min, with backpressure at 150 bar and column temperature at 40 °C. MS detection used positive electrospray ionization with multiple reaction monitoring.

Instrumentation

• Agilent 1260 Infinity Analytical SFC System
• Agilent 6460 Triple Quadrupole LC/MS System with Jet Stream technology
• ZORBAX NH2 column (4.6 × 150 mm, 5 µm)
• Agilent MassHunter software suite for data acquisition and analysis

Results and Discussion

All 13 beta-blockers eluted between 4.68 and 7.38 minutes, achieving baseline separations within a 10 minute runtime. Calibration curves were linear (R2 > 0.9990). Typical LODs were below 1.5 ng/mL and LOQs under 5 ng/mL. Precision measurements at 100 ng/mL showed retention time RSDs ≤ 0.29% and area RSDs ≤ 8%. Analysis of spiked urine yielded a measured concentration of 228.45 ng/mL for penbutolol, with precision and accuracy of 2.28% and 91.38% respectively.

Benefits and Practical Applications

• High throughput analysis supports large sample loads in anti-doping laboratories
• Sensitive and accurate quantification enables both screening and confirmation
• SFC offers rapid run times and efficient separation of polar analytes

Future Trends and Opportunities

The coupling of SFC with advanced triple quadrupole MS is likely to expand for other polar drug screenings. Emerging supercritical stationary phases and automated sample preparation could further accelerate throughput. Integration with high-resolution MS may improve structural confirmation and broaden application in clinical and environmental monitoring.

Conclusion

This work demonstrates a fast and robust SFC-MS protocol for quantifying beta-blockers in urine with excellent sensitivity, precision, and accuracy. The method addresses the high demand for efficient analysis in doping control and clinical diagnostics.

Reference

1. The World Anti-Doping Code Prohibited List International Standard, World Anti-Doping Agency, 2014
2. Mazzarino M et al Screening and Confirmation Analysis by HILIC LC-MS, Journal of Chromatography A, 2011, 1218, 8156–8167